Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B/4 extension study of intracerebroventricular tralesinidase alfa (AX 250) in MPS IIIB
2022-002762-33Phase 3Completed
- Sponsor
- Allievex
- Start
- Sep 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tralesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Allievex. Primary endpoint: Primary safety and tolerability. Started Sep 2022; status: completed.
02
Drugs
tralesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on 2022-002762-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002762-33.